The goal of this clinical trial is to learn whether adebrelimab combined with S-1 works as an adjuvant treatment for patients with cholangiocarcinoma after curative surgery. It will also learn about the safety of this treatment. The main questions it aims to answer are:
* Does adebrelimab combined with S-1 reduce the risk of cancer recurrence after surgery?
* What side effects do participants experience when receiving this treatment? All participants in this study will receive adebrelimab combined with S-1. There is no comparison group in this study.
Participants will:
* Receive adebrelimab by intravenous infusion once every 3 weeks for 4 cycles
* Take S-1 by mouth twice daily for 4 weeks, followed by a 2-week rest, for 4 cycles
* Visit the hospital regularly for checkups, laboratory tests, and imaging examinations (CT or MRI)
* Be followed up for safety and survival after completing treatment